Canadian Stock Trader

Tag: TSX Venture

  • Atlas Energy Corp Reports Second Quarter 2026 Financial Results

    CALGARY, Alberta, Aug. 13, 2026 (GLOBE NEWSWIRE) — Atlas Energy Corp. (“Atlas” or the “Company”) (TSXV: ATLE), a TSXV Sandbox issuer, is pleased to announce its financial and operating results for the three and six months ended June 30, 2026. Selected financial and operational information is outlined below and should be read with Atlas’ consolidated financial statements and management’s discussion and analysis (“MD&A”) as of June 30, 2026, which are available on the Company’s SEDAR+ profile at www.sedarplus.ca.

    Originally published via Source Article.

  • Atlas Energy Corp Reports Second Quarter 2026 Financial Results

    CALGARY, Alberta, Aug. 13, 2026 (GLOBE NEWSWIRE) — Atlas Energy Corp. (“Atlas” or the “Company”) (TSXV: ATLE), a TSXV Sandbox issuer, is pleased to announce its financial and operating results for the three and six months ended June 30, 2026. Selected financial and operational information is outlined below and should be read with Atlas’ consolidated financial statements and management’s discussion and analysis (“MD&A”) as of June 30, 2026, which are available on the Company’s SEDAR+ profile at www.sedarplus.ca.

    Originally published via Source Article.

  • Atlas Energy Corp Reports Second Quarter 2026 Financial Results

    CALGARY, Alberta, Aug. 13, 2026 (GLOBE NEWSWIRE) — Atlas Energy Corp. (“Atlas” or the “Company”) (TSXV: ATLE), a TSXV Sandbox issuer, is pleased to announce its financial and operating results for the three and six months ended June 30, 2026. Selected financial and operational information is outlined below and should be read with Atlas’ consolidated financial statements and management’s discussion and analysis (“MD&A”) as of June 30, 2026, which are available on the Company’s SEDAR+ profile at www.sedarplus.ca.

    Originally published via Source Article.

  • BioSyent Schedules Q2 and H1 2026 Earnings Release for August 20, 2026

    MISSISSAUGA, Ontario, Aug. 13, 2026 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its consolidated financial results for the three and six months ended June 30, 2026 on Thursday, August 13, 2026 after market hours. A presentation on the Company’s second quarter and first half 2026 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.

    Originally published via Source Article.

  • BioSyent Schedules Q2 and H1 2026 Earnings Release for August 20, 2026

    MISSISSAUGA, Ontario, Aug. 13, 2026 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its consolidated financial results for the three and six months ended June 30, 2026 on Thursday, August 13, 2026 after market hours. A presentation on the Company’s second quarter and first half 2026 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.

    Originally published via Source Article.

  • BioSyent Schedules Q2 and H1 2026 Earnings Release for August 20, 2026

    MISSISSAUGA, Ontario, Aug. 13, 2026 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its consolidated financial results for the three and six months ended June 30, 2026 on Thursday, August 13, 2026 after market hours. A presentation on the Company’s second quarter and first half 2026 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.

    Originally published via Source Article.

  • BioSyent Schedules Q2 and H1 2026 Earnings Release for August 20, 2026

    MISSISSAUGA, Ontario, Aug. 13, 2026 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its consolidated financial results for the three and six months ended June 30, 2026 on Thursday, August 13, 2026 after market hours. A presentation on the Company’s second quarter and first half 2026 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.

    Originally published via Source Article.

  • BioSyent Schedules Q2 and H1 2026 Earnings Release for August 20, 2026

    MISSISSAUGA, Ontario, Aug. 13, 2026 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its consolidated financial results for the three and six months ended June 30, 2026 on Thursday, August 13, 2026 after market hours. A presentation on the Company’s second quarter and first half 2026 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.

    Originally published via Source Article.

  • Cygnus Metals Limited: Results of First Court Hearing

    Cygnus Metals Limited: Results of First Court Hearing

    TORONTO and PERTH, Western Australia, Aug. 13, 2026 (GLOBE NEWSWIRE) — Cygnus Metals Limited (ASX:CY5, TSXV:CYG, OTCQB:CYGGF) (Cygnus or the Company) refers to the proposed transaction under which Central Asia Metals PLC (AIM: CAML) (CAML) will acquire 100% of the shares in Cygnus pursuant to a scheme of arrangement under Part 5.1 of the Corporations Act 2001 (Cth) (Corporations Act) (Scheme).

  • Nordique Métaux Critiques fait le point sur le projet de terres rares de Kwyjibo

    MONTRÉAL, Canada, 12 août 2026 (GLOBE NEWSWIRE) — Nordique Métaux Critiques Inc. (anciennement Consolidated Lithium Metals Inc.) (TSXV : NQC | FRA : Z36 | OTCQB : JORFF) (« NQC » ou la « Société ») a le plaisir de faire le point sur ses programmes de travail nécessaires à l’acquisition (l’« Acquisition ») et à l’exercice de son option visant à obtenir une participation indivise pouvant aller jusqu’à 80 % dans le projet de terres rares de Kwyjibo (le « Projet »), sous réserve du respect de certaines conditions.

    Originally published via Source Article.